A growing proportion of modern small-molecule drug candidates are challenged by oral absorption limitations arising from poor solubility, poor permeability, or both. For compounds that also require prolonged exposure, formulation strategy becomes more complex, particularly when once-daily dosing is desirable for chronic therapy, patient convenience, adherence, or competitive product positioning. In these cases, conventional immediate-release or standard modified-release approaches may be insufficient to achieve the desired pharmacokinetic and therapeutic profile.
This presentation will discuss emerging oral formulation strategies that combine amorphous solid dispersions with extended-release design to address both bioavailability and duration of exposure in a single dosage form. By pairing supersaturation-enabling systems with controlled-release architectures, these hybrid approaches offer a path to improve absorption while maintaining targeted release kinetics. Using a series of case studies, we will show how such strategies can be used to better match in vivo pharmacokinetic performance to therapeutic goals and program requirements. The discussion will focus on practical formulation considerations and lessons learned in applying these integrated platforms to next-generation oral medicines.
